002932 明德生物
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入225,618-63.95%749,53710,530,2782,829,830959,099
减:营业总成本319,893-42.99%720,1464,497,1341,120,303405,651
    其中:营业成本108,760-66.40%342,7033,491,170707,026208,995
               财务费用(6,741)-89.73%5,194(34,938)(5,880)(2,611)
               资产减值损失0-100.00%4,753(646,672)0--
公允价值变动收益637--4,5892,7600--
投资收益78,456164.45%120,55035,1206731,310
    其中:对联营企业和合营企业的投资收益(902)-61.82%----(5,776)(6,497)
营业利润82,281-62.49%145,1945,079,8331,697,814562,279
利润总额78,075-63.55%139,8895,076,3971,694,557556,701
减:所得税费用15,711-50.17%70,673695,843247,86981,073
净利润62,364-65.86%69,2164,380,5541,446,688475,628
减:非控股权益(18,575)-149.71%(5,710)172,05733,4636,700
股东净利润80,938-44.30%74,9264,208,4971,413,224468,928

市场价值指针
每股收益 (元) *0.350-44.44%0.33018.4609.9504.990
每股派息 (元) *0.030--0.1205.2004.5002.000
每股净资产 (元) *25.324-3.17%25.91541.61526.59115.967
审计意见 #--标准的无保留意见标准的无保留意见----
回页顶
备注: *未调整数据
#只提供简体内容